ImmunoGen and Aventis develop anticancer drugs; Sanofi and ImmunoGen later amend
ImmunoGen's (cancer therapeutics) expertise in antibodies and Aventis's oncology product development experience will be combined in a three-year collaboration to discover, develop, and market antibody-based cancer treatments. Both partners will provide targets.
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.